June 28, 2026Journal of the American College of Cardiology
Left Ventricular Thrombus Following Acute Myocardial Infarction
Key result
VKAs remain the mainstay therapy for post-AMI LVT over less established DOACs.
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Persistent embolic risk from LV thrombus post-MI warrants anticoagulation; extends evidence for optimized regimens beyond current VKA data.
Key Points
- This research aims to evaluate the incidence and management of left ventricular thrombus following acute myocardial infarction.
- Evaluate incidence trends related to left ventricular thrombus post-myocardial infarction.
- Discuss mechanisms based on Virchow's triad and therapeutic targets.
- Review diagnostic imaging techniques for identifying left ventricular thrombus.
- Incidence of left ventricular thrombus has decreased due to improved therapies.
- Embolic events remain a significant risk, necessitating systemic anticoagulation.
- Vitamin K antagonists are the primary treatment, with limited data on prophylactic anticoagulation.
Structured PICO
P
Population
Patients with acute myocardial infarction at risk of or developing left ventricular thrombus
This review highlights that despite declining incidence, left ventricular thrombus post-myocardial infarction remains a serious complication best managed with vitamin K antagonists, with limited evidence for routine prophylaxis.
Cite This Study
Camaj et al. (2022) conducted a review in Left ventricular thrombus following acute myocardial infarction. Vitamin K antagonists remain the mainstay of therapy for left ventricular thrombus following acute myocardial infarction, as the efficacy of direct oral anticoagulants is less well established.